Targeting MET transcription as a therapeutic strategy in multiple myeloma
Authors:
- 29 May 2008
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 63 (4) , 587-597
Abstract
Multiple myeloma (MM) is an incurable indolent malignancy with an average lifespan of 3 years, underscoring the need for new therapies. Studies have shown that the receptor MET and its ligand hepatocyte growth factor play an important role in proliferation, migration, adhesion, and survival of MM cells. Hence, an effective way to decrease MET receptor may act as a viable therapeutic option. Since MET mRNA and protein have short half-lives, we hypothesized that transcription inhibitor will reduce MET transcript and protein levels and this will lead to cell death. Pharmacological (flavopiridol) and molecular (shRNA) transcription inhibitor were used to impede formation of MET transcripts. The diminution of global RNA synthesis with flavopiridol was related to phosphorylation status of Ser residues (r 2 = 0.90 and 0.92 for Ser2 and Ser5) on the C-terminal-domain of RNA polymerase II. This was accompanied with a time-dependent decrease in MET transcript, which reached to less than 30% (1 μM) and 10% (3 μM) by 24 h. This decline in transcript level was directly associated with a reduction in MET protein level (r 2 = 0.82) and resulted in cell death. Assessment of MET in MM survival was done by using shRNA targeted towards MET. When cells were infected with shRNA viral construct, there was increased cell death with a decline in MET transcript and protein. Taken together, our study demonstrates that MET plays a critical role in the survival and removal or lowering of MET by flavopiridol or shRNA results in the demise of MM cells.Keywords
This publication has 51 references indexed in Scilit:
- A new mechanism for nitric oxide– and cGMP-mediated platelet inhibitionBlood, 2007
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006
- Angiogenesis in multiple myelomaEuropean Journal of Cancer, 2006
- Signalling and survival pathways in multiple myelomaEuropean Journal of Cancer, 2006
- Cyclin D1 Overexpression Increases the Susceptibility of Human U266 Myeloma Cells to CDK Inhibitors through a Process Involving p130-, p107- and E2F-Dependent S-Phase EntryCell Cycle, 2006
- RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and SurvivalCancer Research, 2004
- Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor FlavopiridolClinical Cancer Research, 2004
- Multiple MyelomaHematology-American Society Hematology Education Program, 2001
- Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factorsBritish Journal of Haematology, 1999
- Role of hepatocyte growth factor and its receptorc-met in multiple myelomaMedical Oncology, 1998